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The IGF-1/Akt Pathway Is Neuroprotective
in Huntington’s Disease
and Involves Huntingtin Phosphorylation by Akt
huntingtin and ubiquitin (Davies et al., 1997; DiFiglia et
al., 1997). Nuclear localization of mutant huntingtin is
critical to inducing apoptosis (Saudou et al., 1998; Pe-
ters et al., 1999) by possibly altering transcription (for a
review, see Cha, 2000). Intranuclear inclusions may not
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Children’s Hospital and In addition, huntingtin could mediate some toxicity in
the cytoplasm through interaction with proteins such asDepartment of Neurobiology
Harvard Medical School HAP-1 or HIP-1 (Li et al., 1995; Hackam et al., 2000)
and/or the formation of neuropil aggregates (Li et al.,Boston, Massachusetts 02115
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Currently, there is no treatment to prevent or delayUniversity of California, San Francisco
San Francisco, California 94141 the appearance and progression of symptoms or the
death of HD patients. Several studies have identified
compounds that might be of therapeutic interest in HD:
creatine, histone deacetylase inhibitors, minocycline,Summary
and antiapoptotic proteins or compounds (Saudou et
al., 1998; Chen et al., 2000; Andreassen et al., 2001;In the search for neuroprotective factors in Hunting-
Steffan et al., 2001). Because of their ability to promoteton’s disease, we found that insulin growth factor 1
survival, neurotrophic factors have also been consid-via activation of the serine/threonine kinase Akt/PKB
ered as potential therapeutic agents in neurodegenera-is able to inhibit neuronal death specifically induced
tive disorders. For example, we have shown using anby mutant huntingtin containing an expanded polyglu-
in vitro neuronal model of HD that CNTF and BDNF blocktamine stretch. The IGF-1/Akt pathway has a dual ef-
polyQ-huntingtin-induced cell death (Saudou et al.,fect on huntingtin-induced toxicity, since activation of
1998). In vivo, CNTF has also been shown to be neuro-this pathway also results in a decrease in the formation
protective in rats and monkeys following excitotoxicof intranuclear inclusions of mutant huntingtin. We
lesions that reproduce HD (for a review, see Brouillet etdemonstrate that huntingtin is a substrate of Akt and
al., 1999). One other interesting growth factor is insulinthat phosphorylation of huntingtin by Akt is crucial to
growth factor 1 (IGF-1), which was shown to have neuro-mediate the neuroprotective effects of IGF-1. Finally,
protective effect in several models (for a review, seewe show that Akt is altered in Huntington’s disease
Dore et al., 2000) and could be of interest in HD (Alexipatients. Taken together, these results support a po-
et al., 1999). The ability of IGF-1 to promote cell survivaltential role of the Akt pathway in Huntington’s disease.
has been attributed in part to the phosphatidylinositol
3-kinase/Akt (PI3K/Akt) pathway. Akt, a serine/threonineIntroduction
kinase also known as protein kinase B (PKB) is a potent
survival kinase that exerts its effects by acting on keyHuntington’s disease (HD) is a neurodegenerative disor-
substrates such as components of cell death machineryder characterized by involuntary movements, personal-
or transcription factors (for a review, see Brunet et al.,ity changes, and dementia. The neuropathology of HD
2001).involves a selective death of medium spiny neurons of
In this report, we show that IGF-1 and Akt inhibitthe striatum. The mutation that causes disease is an
mutant huntingtin-induced cell death and formation ofabnormal expansion of a polyglutamine (polyQ) stretch
intranuclear inclusions of polyQ-huntingtin. In addition,in the N terminus of the 350 kDa protein huntingtin, and
we demonstrate that huntingtin phosphorylation by Akta strong inverse correlation exists between the age at
at serine 421 regulates mutant huntingtin-induced toxic-onset in patients and the number of glutamines (Gusella
ity in primary cultures of striatal neurons. These findingsand MacDonald, 2000).
reveal that the specific neuroprotective effect of theThe mechanism by which mutant huntingtin induces
IGF-1/Akt pathway in HD is mediated by direct phos-selective death of striatal neurons is not well under-
phorylation of huntingtin. Finally, we present evidencestood. Several studies have revealed a series of events
that Akt is altered in HD patients, which further supportsthat could ultimately lead to the death of neurons in the
a role of the IGF-1/Akt pathway in the context of HD.striatum (for a review, see Humbert and Saudou, 2001).
When huntingtin contains an expanded polyQ stretch,
it localizes and aggregates in the nucleus as intranuclear Results
inclusions that are formed of N-terminal fragments of
IGF-1 Inhibits Mutant Huntingtin-Induced Cell
Death and Intranuclear Inclusions4 Correspondence: frederic.saudou@curie.u-psud.fr
Previously, we have shown that BDNF and CNTF inhibit5 Present address: Department of Neuroscience, University of Min-
nesota, Minneapolis, Minnesota 55455. mutant huntingtin-induced cell death, but lead to an
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Figure 1. IGF-1 Treatment and Akt Inhibit
Mutant Huntingtin-Induced Cell Death and In-
tranuclear Inclusion Formation
(A) Striatal neurons transfected with 480-17/
68 constructs are treated with IGF-1. Data
from three independent experiments (ANOVA;
F[1, 23] 17.54; P 0.0001) reveal a statistically
significant decrease in survival induced by
480-68 compared to 480-17 without treat-
ment (t[12] 5.97; P 0.0001) but not with IGF-1
treatment (t[11]  0.38; NS). Death induced by
480-68 without treatment is significantly dif-
ferent from all the other cases (Fisher’s analy-
sis: ***P  0.0001).
(B) Data from three independent transfec-
tions reveal a significant decrease in the per-
centage of cells with intranuclear inclusions
induced by the 480-68 construct when
treated with IGF-1 (t[11]  4.49; **P  0.001).
(C) 480-17/68 constructs cotransfected with
Akt c.a. or with the corresponding empty vec-
tor. Data from two independent transfections
(ANOVA; F[1, 26]  16.79; P  0.0001) reveal
a statistically significant decrease in survival
induced by 480-68 compared to 480-17 when
transfected with empty vector (t[14] 6.53; P
0.0001) but not when transfected with Akt c.a.
(t[12]  0.56; NS). Death induced by 480-68
with the empty vector is significantly different
from all the other cases (Fisher’s analysis:
***P  0.0001).
(D) Data from four independent transfections re-
veal that the percentage of striatal neurons ex-
hibiting intranuclear inclusions is significantly
reduced by Akt c.a. (t[18]  2.56; *P  0.05).
increase in the formation of intranuclear inclusions (Sau- and leads to a decrease in the formation of intranuclear
inclusions (Figure 1D). Although we could not evaluatedou et al., 1998). Here, we tested the effect of another
neurotrophic factor, IGF-1, on striatal neurons express- the effect of PI3K inhibition on mutant huntingtin-
induced cell death due to the high toxicity of the PI3King mutant huntingtin. As expected, the 480 amino acid
fragment that contains a mutant stretch of 68 glutamines inhibitor LY in striatal neurons, we found an increase in
the percentage of striatal neurons containing intra-(480-68) induces a statistically significant decrease in
cell survival compared to the wild-type 480-17 con- nuclear inclusions when treated with subtoxic doses of
LY (100 nM; data not shown). Taken together, thesestruct. Interestingly, treatment with IGF-1 completely
blocks mutant huntingtin-induced death of striatal neu- findings indicate that in striatal neurons, IGF-1, through
the activation of the PI3K/Akt pathway, is able to blockrons (Figure 1A) but, in contrast to BDNF and CNTF
treatments, leads to a reduction in the formation of intra- mutant huntingtin-induced cell death and reduces the
nuclear inclusions (Figure 1B). Although IGF-1 is effec- formation of intranuclear inclusions.
tive on the toxicity induced by an N-terminal fragment
of mutant huntingtin, similar results were obtained with
Akt Phosphorylates Huntingtin In Vitrothe physiological form of huntingtin (see Supplemental
Akt could either block mutant huntingtin-induced cellFigure S1 at http://www.developmentalcell.com/cgi/
death and intranuclear inclusion formation by activatingcontent/full/2/6/831/DC1). Taken together, these results
survival signals (Brunet et al., 2001) or by directly actingshow that IGF-1, in addition to inhibiting mutant hunting-
on huntingtin protein. We analyzed the sequences oftin-induced cell death, leads to a decrease in the forma-
huntingtin proteins in various species for the presencetion of intranuclear inclusions.
of an Akt consensus phosphorylation site (Alessi et al.,
1996) and found a putative site conserved between spe-Akt Mediates the Neuroprotective Effect Elicited
cies that we refer to as S421 (serine at position 421 inby IGF-1
the human huntingtin with 23 glutamines).We next examined signaling pathways by which IGF-1
We first asked whether Akt is able to phosphorylateis known to suppress apoptosis and found that in striatal
huntingtin within the 480 amino acid N-terminal frag-neurons, treatment with IGF-1 induces specific activa-
ments that were used to show the neuroprotective effecttion of Akt through the PI3K pathway (see Supplemental
of IGF-1/Akt. We found that an active form of Akt (AktFigure S2). We tested whether the neuroprotective effect
c.a.), but not an inactive form of Akt (Akt k.n.; Dattaof IGF-1 observed in our HD model could be attributed,
et al., 1997), is able to phosphorylate the 480-17/68at least in part, to Akt activation. By cotransfection ex-
fragments of huntingtin (Figure 2A). To demonstrate thatperiments, we found that Akt completely inhibits neu-
ronal death induced by the 480-68 construct (Figure 1C) S421 in the human huntingtin is phosphorylated by Akt,
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Figure 2. Akt Phosphorylates Huntingtin at S421 In Vitro and In Vivo
(A) Akt phosphorylates the 480-17/68 forms of huntingtin. Huntingtin constructs were produced in 293T cells, immunoprecipitated using 4C8
antibody, and incubated with Akt c.a. or k.n. and [-32P]ATP.
(B) In vitro kinase assays were performed using Akt c.a. or k.n. and 4 g of GST-fused proteins as substrates. GST-hu-htt corresponds to
GST-fused human huntingtin (amino acids 384–467). The reaction products were resolved by SDS-PAGE, the gel was stained with Coomassie
blue (CB, lower panel), and the 32P-labeled proteins were visualized by autoradiography (upper panel). Recombinant BAD (1 g) or GSK-3
fusion protein (1 g; Cell Signaling Technology) were used as positive controls of Akt phosphorylation.
(C) Samples obtained as described in (B) were analyzed with anti-P-htt-S421. For immunoblotting, 1/100 of the kinase samples was loaded,
whereas for CB, 1/4 of the kinase reaction was loaded.
(D and E) 293T cells were transfected with various 480-17/68 constructs and Akt c.a. or k.n. Whole-cell extracts were analyzed with the anti-
P-htt-S421 antibody or an anti-htt antibody.
(F) IGF-1 leads to phosphorylation of endogenous huntingtin in a PI3K-dependent manner. SH-SY5Y cells were serum starved (48 hr), incubated
with 10 M LY 294002 (1 hr), and stimulated with 50 ng/ml IGF-1 (30 min). Immunoblotting experiments were performed using the anti-P-htt-
S421 antibody and an anti-htt antibody (2E8). CT, no IGF-1 treatment; NT, no LY treatment prior to IGF-1 stimulation.
(G and H) Whole-cell extracts were analyzed as in (F).
(G) Akt phosphorylates endogenous huntingtin. 293T cells were transfected with an empty vector (CT) or Akt c.a. and serum starved for 18
hr prior to lysis.
(H) Endogenous huntingtin phosphorylation is reduced by a dominant interfering form of Akt. 293T cells were transfected with an empty vector
(CT) or Akt-AAA. Transfected cells were selected by FACS.
we generated huntingtin GST-fused proteins containing with 480-17 or 480-68 with Akt c.a. or k.n. We found
that Akt c.a. induces a phosphorylation of huntingtineither an intact S421 or a serine to alanine mutation at
this site. As shown in Figure 2B, GST-hu-htt is phosphor- at S421 (Figure 2D), indicating that active Akt alone is
sufficient to induce the phosphorylation of huntingtin atylated, while GST-hu-htt-S421A is no longer detectably
phosphorylated by Akt. This shows that S421 is a site S421. We then generated versions of 480-17/68 con-
structs with an S421A mutation and expressed them inof phosphorylation by Akt in huntingtin.
To unequivocally identify S421 as an Akt site, we 293T cells with Akt c.a. (Figure 2E). Levels of huntingtin
were monitored using the 4C8 antibody, revealing noraised a polyclonal antibody that specifically recognizes
huntingtin phosphorylated at S421. As shown in Figure differences in expression due to the S421A mutation.
2C, the antibody to phosphorylated huntingtin S421 The anti-P-htt-S421 recognizes 480-17/68 fragments of
(anti-P-htt-S421) recognizes GST-hu-htt that was incu- huntingtin but fails to recognize the proteins with the
bated with Akt c.a. but fails to recognize nonphosphory- S421A mutation. Thus, we demonstrate that Akt phos-
lated GST-hu-htt or GST-hu-htt-S421A. These results phorylates the 480-17/68 forms of huntingtin in 293T
demonstrate that anti-P-htt-S421 specifically recog- cells at S421.
nizes huntingtin when phosphorylated at S421 and that To test whether endogenous huntingtin becomes
Akt phosphorylates huntingtin at S421 in vitro. Similar phosphorylated in response to IGF-1, we exposed hu-
results were obtained with the mouse huntingtin se- man neuroblastoma SH-SY5Y cells to IGF-1. This treat-
quences (see Supplemental Figure S3). ment induces phosphorylation of huntingtin at S421 as
revealed by anti-P-htt-S421 while the total level of hun-
tingtin protein remained unchanged (Figure 2F). Phos-Akt Phosphorylates Huntingtin In Vivo
phorylation of huntingtin was reduced when cells wereTo determine whether Akt phosphorylation of huntingtin
at S421 occurs in cells, we cotransfected 293T cells treated with the PI3K inhibitor LY. We found that the
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expression of Akt c.a. induces phosphorylation of en- 480-17/68-S421D are expressed in 293T cells and neu-
rons at similar levels as the 480-17/68 constructs (datadogenous huntingtin at S421 (Figure 2G), demonstrating
that the observed phosphorylation of S421 in endoge- not shown).
Taken together, these results indicate that phosphory-nous huntingtin can be due to Akt. We then asked
whether the phosphorylation of endogenous huntingtin lation of huntingtin at S421 is critical to regulating mutant
huntingtin-induced cell death and intranuclear inclusionat S421 can be reduced by the presence of a dominant
interfering form of Akt, Akt-AAA (Wang et al., 1999). 293T formation.
cells were transfected with GFP and Akt-AAA (1:20 ratio).
To increase the percentage of cells expressing the Akt- Full-Length Akt Appears as a Shorter Form
AAA construct, GFP-positive cells were selected by in the Striatum of HD Patients
FACS (Figure 2H). In contrast to FACS-sorted cells trans- Since we show that the IGF-1/Akt pathway blocks mu-
fected with an empty vector, cells expressing Akt-AAA tant huntingtin-induced toxicity, we examined the level
show reduced phosphorylation of endogenous hunting- of Akt in brain samples from HD patients. It is well estab-
tin at S421. Altogether, our findings indicate that in cells, lished that in HD there is a selective atrophy of the
phosphorylation of endogenous human huntingtin is in- brain, with the striatum being affected the most severely.
duced by IGF-1 through a PI3K-dependent mechanism Shrinkage and loss of neurons in the cerebral cortex are
and that huntingtin is a physiological substrate of Akt. also observed but to a lesser extent, while the cerebel-
To determine whether phosphorylation of huntingtin lum is usually unaffected. We analyzed by anti-Akt im-
at S421 occurs in the neuronal model in which mutant munoblotting human samples from control (CT) and HD
huntingtin-induced cell death is blocked by IGF-1, we grade 4 (HD4) and grade 3 (HD3) patients from three
analyzed the status of huntingtin phosphorylation at regions of the brain: cerebellum, cortex, and striatum
S421 after IGF-1 treatment (Figure 3A). Whereas the anti- (Figure 4). Anti--actin antibody is used as a control
P-htt-S421 antibody stains neurons transfected with the for protein levels. Interestingly, in several human brain
480-17/68 constructs, the S421A mutation abolished the samples, Akt appears as two species with relative mo-
anti-P-htt-S421 staining. The S421A mutants of hunting- lecular masses (Mr) of 60 and 49 kDa. These two species
tin are localized in the cytoplasm and neurites of striatal have already been characterized as Akt full-length (Mr,
neurons as for wild-type and polyQ-huntingtin. Taken 60 kDa) and a caspase-3-generated Akt product (Mr, 49
together, these data demonstrate that in 293T cells, kDa; Bachelder et al., 1999; Francois and Grimes, 1999;
human neuroblastoma cells, and striatal neurons, IGF-1 Rokudai et al., 2000). In the CT samples, from the cere-
induces phosphorylation of huntingtin at S421. bellum, cortex, and striatum, the lower Akt species is
absent, except for sample 3 where a weak signal is
observed in the cortex. In contrast, in HD patients theMutant Huntingtin-Induced Toxicity Is Regulated
shorter Akt product is observed in the cerebellum forby Phosphorylation at S421
HD samples 5–9 and in the cortex for HD samples 4 andTo analyze the biological relevance of huntingtin S421
6–8. More strikingly, in the striatum, the two HD samplesphosphorylation, we tested the effect of the S421A mu-
show a high accumulation of the lower species in com-tation in huntingtin on cell survival. We found that the
parison to the CT samples, where the 49 kDa species480-68 and 480-68-S421A constructs elicit similar loss
is totally absent. Furthermore, in the striatum of HDof survival in striatal neurons (Figure 3B). We next com-
patients, full-length Akt is either low (sample 5) or almostpared the ability of IGF-1 to increase the survival of
undetectable (sample 9; a weak band appears afterneurons expressing the 480-68 constructs with or with-
overexposure; data not shown). We could not detectout the S421A mutation. Interestingly, while IGF-1 is
phosphorylated forms of huntingtin and Akt in brainable to completely inhibit death induced by the 480-
samples, probably due to postmortem intervals (data68 construct, survival was not fully recovered by IGF-1
not shown).treatment with the 480-68-S421A construct. This result
In conclusion, we observed a pronounced alterationdemonstrates that the complete inhibition of mutant
of Akt in the most affected brain region of HD patients,huntingtin-induced cell death by IGF-1 requires the
the striatum. These observations further support a po-presence of an intact S421 in huntingtin protein. It is
tential role of Akt in HD.worthwhile to note that we observed an increase in the
survival of neurons expressing the 480-68-S421A after
IGF-1 treatment (Figure 3B). This indicates that IGF-1, Discussion
in addition to promoting survival through the phosphory-
lation of huntingtin at serine 421, elicits some neuropro- We show here that phosphorylation of S421 in polyQ-
huntingtin abrogates its proapoptotic activity. The ab-tection against mutant huntingtin by other mechanisms.
We next asked whether constitutive phosphorylation sence of phosphorylation at S421 or its constitutive
phosphorylation do not appear to affect the level ofof huntingtin at S421 is able to reduce toxicity of mutant
huntingtin. To test this hypothesis, we generated a 480- expression or the subcellular localization of huntingtin.
Further, phosphorylation of huntingtin at S421 does not68 construct in which serine 421 is changed into an
aspartic acid to mimic constitutive phosphorylation. modify its ability to be ubiquitinated or degraded (data
not shown). In addition, we do not observe any effectsWith this S421D mutation, we found that polyQ-hunting-
tin is no longer able to induce neuronal death (Figure 3C) of the phosphorylation at S421 on the cleavage of hun-
tingtin by calpain or caspases -1 and -3 (data not shown).and leads to a reduction in the percentage of neurons
containing intranuclear inclusions (Figure 3D). The effect Huntingtin interacts with several proteins (Humbert and
Saudou, 2001). It is possible that phosphorylation altersis not due to differences in expression levels, since the
IGF-1/Akt Pathway and Huntington’s Disease
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Figure 3. Phosphorylation of S421 Regulates Mutant Huntingtin-Induced Toxicity
(A) Huntingtin is phosphorylated at S421 in striatal neurons. Striatal neurons were transfected, treated with IGF-1 (50 ng/ml; 1 hr), fixed,
immunostained with the 4C8 and anti-P-htt-S421 antibodies, and analyzed by deconvolution microscopy.
(B) IGF-1 suppresses mutant huntingtin-mediated cell death in an S421 phosphorylation-dependent manner. Data from three independent
experiments (ANOVA; F[3, 45]  18.44; P  0.0001) reveal that survival induced by IGF-1 on the 480-68-S421A construct is significantly lower
than the survival induced by IGF-1 on the 480-68 construct (t[12]  3.53; **P  0.01) and, significantly different from all other cases (Fisher’s
analysis: **P  0.01). Death induced by the 480-68 and 480-68-S421A constructs without treatment is significantly different from all the other
cases (Fisher’s analysis: ***P  0.0001).
(C) S421D mutation of huntingtin abolishes polyQ-dependent cell death. Data from three independent experiments (ANOVA; F[3, 26]  23.97;
P 0.0001) reveal that survival induced by the 480-68-S421D construct is significantly higher than the survival induced by the 480-68 construct
(t[13]  7.48; P  0.0001) but not from the survival elicited by the 480-17 construct (t[13]  0.86; NS) or the 480-17-S421D construct (t[14]  0.057;
NS). Death induced by the 480-68 construct is significantly different from all the other cases (Fisher’s analysis: ***P  0.0001).
(D) Data from two independent transfections revealed that the percentage of intranuclear inclusions formed by the 480-68-S421D is lower
than for the 480-68 construct (t[8]  4.55; **P  0.002).
the ability of huntingtin to interact with a yet to be identi- nine neurodegenerative disorders, including HD. Our ex-
periments demonstrate that toxicity of mutant huntingtinfied protein.
Although we find that the complete neuroprotective can be inhibited by direct phosphorylation and raise
the possibility that phosphorylation by Akt could alsoeffect mediated by IGF-1 requires phosphorylation of
mutant huntingtin at S421, in the absence of phosphory- abrogate the toxicity of other proteins containing an
expanded polyQ tract. One interesting candidate is thelation of huntingtin, IGF-1 is still able to induce some
neuroprotection. This suggests that in the context of androgen receptor whose CAG expansion results in spi-
nal and bulbar muscular atrophy (SBMA) or Kennedy’smutant huntingtin-induced cell death, IGF-1 mediates
its neuroprotective effect not only via a direct action of disease (Fischbeck et al., 1999). Indeed, the androgen
receptor has recently been shown to be a substrate ofAkt on huntingtin protein but also via the phosphoryla-
tion of other substrates that increase neuronal survival. Akt (Lin et al., 2001). However, it is not known whether
this phosphorylation plays a role in the toxicity inducedSeveral substrates of Akt such as Bad, FOXOs, and
caspase-9 that promote neuronal survival when phos- by the mutant polyQ androgen receptor. By scanning
proteins that contain an expanded polyQ stretch andphorylated by Akt have been described (Brunet et al.,
2001). Those substrates, as well as others that remain that are responsible for this class of neurodegenerative
disorders, we found, for example, that ataxin-1, the pro-to be identified, could also participate in mediating the
neuroprotective effect elicited by IGF-1 and Akt on mu- tein responsible for spinal and cerebellar ataxia type 1,
contains a putative phosphorylation site for Akt (datatant huntingtin-induced cell death.
Expansion of CAG trinucleotide repeats in otherwise not shown). If phosphorylation by Akt inhibits death in-
duced by mutant ataxin-1, together with this study, weunrelated proteins is known to be the cause of at least
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as well as developing drugs that activate and/or prevent
alteration of the Akt pathway could possibly lead to new
therapeutic interventions in HD.
Experimental Procedures
Descriptions of constructs, cell culture, transfection, and protein
extracts may be found as supplemental data at h t t p : / / w w w .
developmentalcell.com/cgi/content/full/2/6/831/DC1.
Huntingtin Phospho-Antibody S421
A phosphopeptide of the following sequence was synthesized:
CSGGRSRSGpSIVELI, and coupled to KLH (Neosystem, Illkirch,
France). A polyclonal antibody to the KLH-coupled peptide was
obtained and affinity purified as previously described (Neosystem;
Datta et al., 1997).
Brain Tissues
Tissues were obtained from the Harvard Brain Tissue Resource
Center as follows: three controls (samples 1–3), three HD grade 4
(samples 4–6), and three grade 3 (samples 7–9) patients. Samples
1–9 correspond, respectively, to brain numbers 4741, 4744, 4751,
4680, 4740, 4798, 4719, 4754, and 4797 as numbered by the Harvard
Brain Tissue Resource Center.
Immunocytochemistry and Immunoblotting
Antibodies used include anti-huntingtin 4C8 and 2E8 (ICC, 1:500;
WB, 1:5000; Trottier et al., 1995), anti-phospho-huntingtin-S421
Figure 4. Akt Appears as a Shorter Form in Huntington’s Disease
(ICC, 1:100; WB, 1:200), anti-ubiquitin (1:100; DAKO), anti-Akt
Patients
(1:1000; New England Biolabs), anti-phospho-Akt Ser473 (1:1000;
Protein extracts were prepared from cerebellar, cortical (Brodmann New England Biolabs), and monoclonal anti--actin AC15 (1:5000;
area 9), or striatal postmortem samples, resolved by SDS-PAGE, Sigma).
and immunoblotted with anti-Akt or anti--actin antibodies. Brain
tissues are from control (CT; samples 1–3) and HD grade 4 (HD4; Measurement of Neuronal Survival
samples 4–6) and grade 3 (HD3; samples 7–9) patients. PMI (hr), and Intranuclear Inclusions
postmortem interval. For survival assays, striatal neurons were transfected with the plas-
mids of interest and the CMV-GFP plasmid (6:1 ratio). Twelve hours
and 2 days after transfection, GFP-positive neurons were scored
under fluorescence microscopy in a blinded manner. For intra-would have evidence for a common mechanism of neuro-
nuclear inclusion scoring, transfected and immunostained neuronsprotection in polyQ tract neurodegenerative disorders.
6 days after transfection were analyzed for the presence of ubiquitin-
Features of apoptosis within the degenerating neu- positive intranuclear inclusions in a blinded manner. Each graph
rons are observed in postmortem brains from HD pa- represents two to three independent experiments performed in tripli-
tients (Portera-Cailliau et al., 1995). Activation of apopto- cates. Data are expressed as the mean value  SEM. Each bar in
a given graph corresponds to the scoring of about 2000 neurons insis has also been reported in mouse and cellular models
cell death experiments and to 500 neurons for inclusions scoring.of HD and could be associated with an activation of
caspases (Reddy et al., 1998; Saudou et al., 1998;
Kinase AssaysHackam et al., 2000; Li et al., 2000b). Caspases cleave
293T cells were transfected with HA-Akt vectors. Twenty-four hours
specific target proteins during apoptotic death including after transfection, extracts were obtained and kinase assays were
signaling molecules that promote cell survival. In partic- performed as described (Datta et al., 1997).
ular, Akt has been shown to be negatively regulated by
Acknowledgmentsapoptotic signaling pathways in vivo (Widmann et al.,
1998; Bachelder et al., 1999). In vitro, Akt is cleaved
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